Dawson Keith
University of San Francisco, San Francisco, California, USA.
J Infus Nurs. 2013 May-Jun;36(3):172-8. doi: 10.1097/NAN.0b013e318288a103.
The majority of follicular non-Hodgkin's lymphoma patients in the United States receive an initial treatment strategy that includes the infusion of rituximab. Data from a phase III multicenter clinical trial led to the 2012 US Food and Drug Administration approval of a 90-minute infusion of rituximab (Rituxan) starting at Cycle 2 for patients with non-Hodgkin's lymphoma who did not experience a Grade 3 or 4 infusion-related adverse event during Cycle 1. A review of literature was undertaken to identify existing evidence regarding both the safety of rituximab faster infusion and its impact on nursing practice. The aim of this article is to stimulate discussion and lead to implementation of evidence-based nursing practices to improve the delivery of patient care.
美国大多数滤泡性非霍奇金淋巴瘤患者接受的初始治疗策略包括输注利妥昔单抗。一项III期多中心临床试验的数据促使美国食品药品监督管理局于2012年批准，对于在第1周期未发生3级或4级输注相关不良事件的非霍奇金淋巴瘤患者，从第2周期开始将利妥昔单抗（美罗华）的输注时间缩短至90分钟。我们进行了文献综述，以确定关于利妥昔单抗更快输注的安全性及其对护理实践影响的现有证据。本文旨在激发讨论，并促使实施循证护理实践，以改善患者护理服务。
